Wednesday, February 23, 2011 3:19:15 PM
What is more interesting is the factory and the ability to ramp up manufacturing which will have a direct impact on the bottom line (and as a result the stock price).
what i would be interested in hearing is what prospects they have to (quickly) monetize on their additional output capacity once it is online and when that will be. (Having a factory by itself is not going to do much).
I spoke to David Corner (not the first time by the way) who is the person responsible for creating the in-house investor relations program. Comes across as quite knowledgeable but he didn't say anything I didn't already know from doing my own research.
He was quite open with me in sharing what he is working on but I have to say I was somewhat frustrated by his "take it or leave it" attitude. Got the impression he is less concerned about investor opinion than working his plan (friendly but arrogant).
The factory and expanded sales is the key I think to this stock going up anytime soon (the drug status stuff is a long shot) and that is the main reason I choose to invest in this company in the first place.
I am going to stick with it a little longer but come April/May, there has to be some solid news.
THE FACTORY IS THE KEY!!!!
Recent CYTH News
- Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 • Business Wire • 06/25/2024 01:25:00 PM
- Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 06/14/2024 08:01:00 PM
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 • Business Wire • 05/30/2024 01:00:00 PM
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Business Wire • 05/16/2024 12:05:00 PM
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/18/2024 01:05:00 PM
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease • Business Wire • 03/14/2024 01:34:00 PM
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 03/13/2024 09:04:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2024 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:46:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:45:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:44:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:43:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:42:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:41:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:40:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:44:54 PM
- Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office • Business Wire • 01/29/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:01:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:50:39 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 02:48:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:28:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:25:09 AM
- Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. • Business Wire • 12/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:21 PM
- Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1 • Business Wire • 12/18/2023 02:15:00 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM